# Lenvatinib

## Lenvima 4mg

##### 臨採

| TAH Drug Code      | [OLENV](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OLENV)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | 1. Differentiated thyroid cancer (DTC): Used for adults with progressive, locally advanced, or metastatic DTC, unresponsive to radioactive iodine treatment. 2. Renal cell carcinoma (RCC): Used as a first-line treatment in combination with pembrolizumab for advanced RCC patients. Also used in combination with everolimus for advanced RCC patients who have received prior anti-angiogenic therapy. 3. Hepatocellular carcinoma (HCC): Suitable for advanced HCC patients who are ineligible for surgical resection or local therapies. 4. Endometrial carcinoma (EC): Used in combination with pembrolizumab for advanced EC patients who have had disease progression after systemic therapy and are not candidates for curative surgery or radiotherapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Dosing             | Endometrial cancer, Carcinoma, advanced disease, that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), in combination with pembrolizumab in patients with disease progression following prior systemic therapy in any setting who are not candidates for curative surgery or radiation: 20mg QD PO + pembrolizumab 200mg IV over 30 minutes Q3W. Liver carcinoma, Unresectable, first-line therapy: (<60kg) 8mg QD PO, (>=60kg) 12mg QD PO. Renal cell carcinoma, Advanced, in combination with everolimus, after 1 prior anti-angiogenic therapy: 18mg QD PO + everolimus 5mg QD PO. Renal cell carcinoma, Advanced, in combination with pembrolizumab, first-line treatment: 20mg QD PO + pembrolizumab 200 mg IV over 30 minutes Q3W up to 2 years; following 2 years of combination therapy, may give lenvatinib as a single agent until disease progression or unacceptable toxicity. Thyroid cancer, Differentiated, locally recurrent or metastatic, progressive, refractory to radioactive iodine: 24mg QD PO                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Contraindications  | Hypersensitivity to Lenvima or any component of the formulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Adverse Effects    | Common: Hypertension (42-73%), Peripheral edema (14-42%), Hand-foot syndrome due to cytotoxic therapy (23-32%), Impaired wound healing, Rash (14-37%), Hypothyroidism (21-67%), Abdominal pain (31-37%), Constipation (16-29%), Decrease in appetite (34-54%), Nausea (20-49%), Stomatitis (35-44%), Vomiting (16-48%), Weight decreased (30-51%), Hemorrhage (23-35%), Arthralgia, Disorder of the musculoskeletal system (53%), Myalgia, Headache (10-38%), Proteinuria (26-34%), Urinary tract infectious disease (11-31%), Cough (24-37%), Difficulty talking (18-31%), Dysphonia (22-30%), Dyspnea (35%), Fatigue (44-73%) Serious: Myocardial dysfunction (7-10%), Myocardial infarction, Prolonged QT interval (2-11%), Right ventricular dysfunction, Diarrhea (39-81%), Gastrointestinal obstruction, Malignant, Lower gastrointestinal hemorrhage, Perforation of the intestine, Anemia (Renal cell carcinoma, 6%), Arterial thrombosis (2-5%), Myelodysplastic syndrome, Thrombocytopenia (Renal cell carcinoma, 5%), Hepatic encephalopathy (Hepatocellular carcinoma, 8%), Hepatitis, Hepatorenal syndrome, Hepatotoxicity (25%), Liver failure, Osteonecrosis of the jaw (0.4%), Posterior reversible encephalopathy syndrome (0.3%), Acute injury of the kidney, Nephritis, Renal failure (Renal cell carcinoma, 18%), Renal impairment (7-18%), Pneumonia, Pneumonitis, Pulmonary embolism, Cardiorespiratory arrest, Dehydration (9-10%), Multiple organ failure, Sepsis |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| More Info          | [UpToDate](https://www.uptodate.com/contents/lenvatinib-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

